Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

13.95 -2.60 (-15.71%)

Delayed Quote Updated: 4:00 PM EDT, Oct 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Syndax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 06, 2025

Via Benzinga

Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

May 05, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For May 5, 2025 ↗

May 05, 2025

Via Benzinga

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 02, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Pharmaceuticals's Earnings: A Preview ↗

November 04, 2024

Via Benzinga

NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

April 29, 2025

Via Benzinga

Why Leggett & Platt Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

April 29, 2025

Via Benzinga

Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

April 28, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

April 02, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax's Revuforj Earns Strong Physician Support, JP Morgan Predicts Sales Growth ↗

March 21, 2025

JP Morgan raised Syndax's price target to $41, citing strong early Revuforj sales and physician confidence in its use for acute leukemias and NPM1 AML.

Via Benzinga

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

March 05, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 03, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For March 3, 2025 ↗

March 03, 2025

Via Benzinga

Syndax Announces Participation in March Investor Conferences

February 25, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

February 24, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks ↗

January 17, 2025

Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with unknowns.

Via Investor's Business Daily

Topics Government

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday ↗

November 18, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 12, 2024

Via Benzinga

Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer ↗

November 12, 2024

Syndax Pharmaceuticals announces positive Phase 2 trial results for revumenib in relapsed/refractory mNPM1 AML, with key milestones expected in 2024 and 2025.

Via Benzinga

This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

October 24, 2024

Via Benzinga

FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication ↗

August 15, 2024

The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at least two prior therapies, providing new hope for those with this serious...

Via Benzinga

Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

August 14, 2024

From Incyte and Syndax Pharmaceuticals

Via Business Wire

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

August 01, 2024

From Sagimet Biosciences Inc.

Via GlobeNewswire

3 Biotech Stocks That Could Make Your Summer Unforgettable ↗

July 30, 2024

If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider.

Via InvestorPlace

Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies

June 17, 2024

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END

Via FinancialNewsMedia

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

June 10, 2024

From Pyxis Oncology

Via GlobeNewswire

Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies

June 17, 2024

From FN Media Group LLC

Via GlobeNewswire

Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket ↗

May 29, 2024

Via Benzinga

SNDX Stock Earnings: Syndax Pharmaceuticals Beats EPS for Q1 2024 ↗

May 08, 2024

SNDX stock results show that Syndax Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.